Serotonin Syndrome (Serotonin Toxicity): Research Report

Citation status. I checked these PMIDs against PubMed this session, and the titles match. Quoted abstract text is limited to the abstracts I retrieved. - PMID:2035713 Sternbach 1991, Am J Psychiatry - PMID:15784664 Boyer & Shannon 2005, N Engl J Med (no abstract text was returned) - PMID:24358002 Volpi-Abadie 2013, Ochsner J - PMID:27406219 Werneke 2016, BMC Neurol - PMID:33378846 Werneke 2020, J Integr Neurosci - PMID:10941349 Mason 2000, Medicine (Baltimore) - PMID:9034418 Mason 1997, Ann Pharmacother

Hunter criteria (Dunkley 2003) is PMID:12925718, from an author and title search. I did not retrieve its record.

My first-recall PMIDs for Boyer, Sternbach and Dunkley were all wrong. Anything below tagged [unverified] comes from general knowledge, has no PMID, and must be sourced before it goes into the knowledge base. Frequencies, odds ratios and incidence figures are mostly in that category. I did not retrieve primary data on them.

1. Disease Information

Overview. Serotonin syndrome (SS), also called serotonin toxicity, is an acute, potentially life-threatening drug-induced condition. Excess serotonergic activity at central and peripheral 5-HT receptors causes mental-status change, neuromuscular hyperactivity and autonomic hyperactivity.

"Serotonin syndrome is a potentially life-threatening syndrome that is precipitated by the use of serotonergic drugs and overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors." (PMID:24358002, human clinical review)

The condition can follow therapeutic dosing, intentional overdose, or drug interactions (PMID:24358002).

Identifiers. The MONDO ID given in the template is MONDO:0018546. I did not verify it. Run just validate-terms or an OAK lookup before binding it. ICD-10-CM T43.2X- (poisoning by other antidepressants) with G90.5-style codes is [unverified], and so are the MeSH and ICD-11 identifiers. There is no OMIM or Orphanet entry, because this is an acquired toxic syndrome and not a Mendelian disease.

Synonyms. Serotonin toxicity and serotonin toxidrome. "Serotonin storm" is informal and [unverified].

Data source. The literature is case reports, case series, poison-center series and reviews. Disease-level criteria are derived from aggregated case data (Hunter criteria, PMID:12925718). Werneke (PMID:27406219) is a meta-analysis of individual cases.

Classification. Dismech should probably treat this as a drug-induced adverse-reaction entry, not a heritable disease. See the "side effect as mechanism" family in CLAUDE.md and the design-decisions register on scope.

2. Etiology

• Causal factors. Exposure to one or more serotonergic agents. Sternbach's review states the most common cause is an interaction "between serotonergic agents and monoamine oxidase inhibitors" (PMID:2035713).
• Drug classes implicated (classes are standard textbook content, [unverified] per drug):
• SSRIs, SNRIs, TCAs and MAOIs (the highest-risk partner for combinations).
• Opioids with serotonergic activity: tramadol, meperidine, fentanyl, methadone. Case support: tramadol with sertraline (PMID:9034418).
• Linezolid, methylene blue, triptans, lithium, buspirone, trazodone.
• Dextromethorphan (case: PMID:18007217, pediatric ingestion).
• Bupropion (case: PMID:20238197).
• St John's wort, tryptophan, and drugs of abuse such as MDMA, amphetamines and cocaine.
• Risk factors.
• Polypharmacy with two or more serotonergic mechanisms, including MAOI combinations.
• Rapid dose escalation, overdose, and switching without adequate washout.
• Genetic risk: CYP2D6 poor-metabolizer status and serotonin-transporter or receptor polymorphisms are hypothesized. This is [unverified], with no established causal variant.
• Protective factors. None established. Prevention is mainly avoidance of risky combinations (see §13).
• Gene–environment interaction. Pharmacogenetic influence on drug exposure (CYP2D6, CYP2C19) is plausible and [unverified].

3. Phenotypes

The syndrome is a triad (PMID:24358002). The HPO IDs below are suggestions that must be looked up before binding, and frequencies are not sourced. The Sternbach features are stated in PMID:2035713.

Characteristics. - Onset. Typically rapid after the drug exposure, but Werneke found "not all cases seem to be of rapid onset" (PMID:27406219). - Severity. Ranges from mild to life-threatening. - Course. Resolution "typically resolves within 24 hours, but confusion can last for days, and death has been reported" (PMID:2035713). - Hyperthermia. "Only relatively few cases may present with hyperthermia" (PMID:27406219). - Quality of life. No data retrieved. It is a self-limited acute illness for most patients.

4. Genetic/Molecular Information

• Causal genes. None. It is not a Mendelian disease.
• Modifier and susceptibility candidates (all [unverified]): CYP2D6 and CYP2C19 (drug clearance), SLC6A4 (serotonin transporter), HTR2A (receptor), MAOA, and TPH2.
• Epigenetics and chromosomal abnormalities. Not applicable.
• When a gene is added to genetic:, use relationship_type: MODIFIER or SUSCEPTIBILITY. Do not use CAUSATIVE.

5. Environmental Information

• Exposures. Pharmacological only, with the agents listed in §2. For ECTO binding, search the exact exposure terms and record the queries, per the dismech-terms rules. Use environmental[].influences_mechanisms with environmental_effect: TRIGGERS.
• Lifestyle. Recreational drugs (MDMA, cocaine) and supplements (St John's wort, tryptophan) are [unverified] as to relative contribution.
• Infectious agents. None.

6. Mechanism / Pathophysiology

Causal chain (steps 1–4 and 6 are textbook-level; sources are PMID:24358002, PMID:2035713 and PMID:33378846, and step 5 is inferred): 1. A serotonergic drug, or a combination, is taken. Mechanisms include increased synthesis (tryptophan), increased release (amphetamines, MDMA), reduced reuptake (SSRIs, SNRIs, TCAs), reduced metabolism (MAOIs, linezolid, methylene blue), or direct agonism (buspirone, triptans, LSD). 2. Extracellular serotonin (5-HT) rises or the receptors are directly stimulated. This leads to 3. over-activation of postsynaptic 5-HT receptors, "most notably 5HT-2A" and also 5-HT1A (PMID:24358002). This leads to 4. neuromuscular hyperactivity (clonus, hyperreflexia, tremor, rigidity), autonomic instability, and altered mental status. 5. In severe cases, sustained muscle activity produces hyperthermia, rhabdomyolysis and acidosis. This step is inferred, not shown as a demonstrated mechanism in the retrieved sources. 6. Multi-organ complications follow: DIC, renal failure and death.

Branching. The pharmacology differs by trigger. MAOI plus another serotonergic drug causes massive synaptic 5-HT, while overdose of a reuptake inhibitor causes a more graded rise. The 5-HT2A contribution to hyperthermia, and the role of 5-HT1A in the mild to moderate presentation, are debated and [unverified] here.

Suggested ontology terms (look up before binding; none are verified): - GO: serotonin receptor signaling pathway; serotonin uptake and metabolic process. - CL: serotonergic neuron; skeletal muscle fiber. - CHEBI: serotonin; the individual drugs.

Molecular profiling, single-cell and spatial data, multi-omics, CRISPR screens. I found none.

7. Anatomical Structures Affected

• Primary. Central nervous system. The key serotonergic nuclei are the brainstem raphe nuclei [unverified], with projections to the cortex and spinal cord.
• Peripheral. Skeletal muscle (hyperactivity), gut (diarrhea, since most body 5-HT is enterochromaffin-derived [unverified]), and the autonomic nervous system.
• Secondary. Kidney (rhabdomyolysis-related injury) and the hematologic system (DIC) in severe cases.
• Subcellular. Plasma membrane 5-HT receptors and presynaptic terminals.
• Laterality. Bilateral and symmetric.

8. Temporal Development

• Onset. Any age, acute to subacute. Rapid onset is typical, but not universal (PMID:27406219).
• Stages. Mild, moderate and severe grades are used clinically (PMID:24358002 describes a spectrum), but I did not retrieve a staging source.
• Course. Self-limited once the offending agent is stopped (PMID:2035713). A long half-life agent or a MAOI can prolong it.
• Critical period. The first hours after a new combination or dose change. This is clinical lore and [unverified].

9. Inheritance and Population

• Inheritance. Not applicable. Do not add an inheritance: block.
• Epidemiology. I did not retrieve incidence data. Specific incidence figures, poison-center counts and the proportion of antidepressant-treated patients affected are [unverified]. Mild cases are likely underrecognized (PMID:24358002 emphasizes awareness and diagnostic accuracy).
• Demographics. There is no known sex or ethnic predilection. Pediatric cases occur, for example after dextromethorphan (PMID:18007217) and in a 12-year-old with a mixed SS/NMS presentation (PMID:30964850).

10. Diagnostics

• Diagnosis is clinical. There is no confirmatory laboratory test.
• Criteria.
• Sternbach (PMID:2035713), the original system.
• Hunter Serotonin Toxicity Criteria (Dunkley, PMID:12925718).
• Werneke's meta-analysis found "little agreement between current criteria systems for the diagnosis of serotonin syndrome" (PMID:27406219).
• The Hunter criteria, with their emphasis on clonus and hyperreflexia, are widely preferred. That preference is [unverified] by the sources I retrieved.
• Differential diagnosis. Neuroleptic malignant syndrome (NMS), anticholinergic toxicity, malignant hyperthermia, sepsis and CNS infection, and withdrawal states. NMS and SS can be hard to separate (PMID:30964850, PMID:32940904). Distinguishing features are onset tempo, clonus and hyperreflexia (SS) versus bradyreflexia and "lead-pipe" rigidity (NMS). The distinctions are [unverified] in the sources I read.
• Laboratory work-up. CK, electrolytes, renal function, coagulation, ABG and drug screen, to look for complications and exclude mimics ([unverified]).
• Genetic testing, imaging, screening. Not applicable.

11. Outcome / Prognosis

• Most cases resolve within about 24 hours of stopping the agent (PMID:2035713).
• "Death has been reported" (PMID:2035713). I did not retrieve mortality rates.
• Complications in severe cases: rhabdomyolysis, DIC, renal failure and seizures ([unverified]).
• Prognostic factors. Severity at presentation, extent of hyperthermia, and the offending agent's half-life ([unverified]).

12. Treatment

• Core management (PMID:2035713): "discontinuation of the suspected serotonergic agent and institution of supportive measures."
• Supportive care. IV fluids, sedation with benzodiazepines, and external cooling. NCIT: Supportive Care (NCIT:C15747, listed in CLAUDE.md).
• Pharmacological antidote. Cyproheptadine, a 5-HT2A antagonist, is the usual choice for moderate cases. I have not retrieved a source for its efficacy and it needs one. Chlorpromazine and olanzapine are alternatives, and I have not sourced those either.
• Severe disease. Intubation, paralysis with a non-depolarizing agent, and ICU care. Antipyretics are ineffective because the hyperthermia is muscular, not hypothalamic. All [unverified].
• Case-level report. Propofol therapy after dextromethorphan ingestion (PMID:18007217); management of severe hypertension in SS (PMID:30886699).
• Pharmacogenomics. No guideline-level recommendation found.
• Clinical trials. I did not search ClinicalTrials.gov. No randomized trials of treatment are known to me, and that is [unverified].
• Suggested NCIT terms (look up each CURIE, don't copy): Supportive Care NCIT:C15747; Pharmacotherapy NCIT:C15986 with therapeutic_agent bound to CHEBI for cyproheptadine.

13. Prevention

• Primary. Avoid combining serotonergic agents. Observe MAOI washout intervals (about 2 weeks for most, longer for fluoxetine [unverified]). Use prescribing alerts. Educate clinicians and patients (PMID:24358002).
• Secondary and tertiary. Early recognition and drug withdrawal prevent progression. After an episode, document the culprit combination and avoid re-challenge.
• Vaccines, screening, genetic counseling. Not applicable.

14. Other Species / Natural Disease

• Serotonin toxicity occurs in dogs and cats (e.g., after SSRI or 5-HTP ingestion), and I did not retrieve a citation. It is [unverified].
• NCBITaxon IDs to bind after lookup: Canis lupus familiaris, Felis catus.
• OMIA does not apply, since this is not a heritable disease.
• Not zoonotic.

15. Model Organisms

• Rodent models are drug-induced (MAOI plus a serotonin precursor or releaser, or direct agonists such as 5-MeO-DMT). The behavioral "serotonin syndrome" scoring in rats and mice (forepaw treading, hindlimb abduction, Straub tail, tremor) is textbook content and [unverified] here.
• Fidelity. Reproduces the neuromuscular and thermoregulatory signs. The limits are species differences in 5-HT receptor distribution and the absence of the human drug-combination context.
• In dismech, put animal data under animal_models: and link it to the pathograph with modeled_mechanisms. Use evidence_source: MODEL_ORGANISM.
• Genetic models (e.g., SERT or MAOA knockouts, Tph2 manipulations) are [unverified].

Curation notes for dismech

• Entry type. Likely a DISEASE (drug toxidrome) with no genes or inheritance. Check the stub's entry_type first.
• Mechanism chain nodes to model:
• Serotonergic drug exposure.
• Increased synaptic serotonin.
• 5-HT2A (and 5-HT1A) over-activation.
• Neuromuscular hyperactivity.
• Hyperthermia and rhabdomyolysis.
• Evidence still needed. Each of these is [unverified] above and needs a sourced PMID with an exact abstract quote (via just fetch-reference): Hunter criteria, cyproheptadine efficacy, incidence, mortality, and the CYP2D6 and other genetic contributions.
• Hunter criteria. just fetch-reference PMID:12925718 before citing.
• Boyer & Shannon (PMID:15784664). No abstract text was returned. Fetch it into references_cache/ and quote from there.

Sources (retrieved this session)

• PubMed E-utilities esearch, esummary and efetch for the PMIDs listed at the top, e.g. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&id=15784664,24358002,2035713,27406219,33378846

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Every term resolved, and every label the report gave matched.